Menu

First Direct-to-Consumer BRCA Test Authorized by FDA

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

Mar 6, 2018
Kerry Grens

ISTOCK, PHOTOVIDEOSTOCKThe Food and Drug Administration (FDA) has allowed the direct-to-consumer genetics company 23andMe to offer a test for mutations in the BRCA1 and BRCA2 genes, the agency announced today (March 6). The three mutations included in the screen increase the risk of breast and ovarian cancer, and are most common among people of Ashkenazi Jewish decent.

“Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is a major milestone for 23andMe and for the consumer,” Anne Wojcicki, 23andMe CEO and cofounder, says in a press release.

The FDA made a point to note that there are more than 1,000 cancer-related mutations in BRCA genes, and just about 2 percent of Ashkenazi Jewish women carry the three mutations in the test. They are rarely found outside this group. According to 23andMe, any of the variants increase a woman’s chance of breast cancer before age 70 by 45 percent to 85 percent.

“While the detection of a BRCA mutation on this test does indicate an increased risk, only a small percentage of Americans carry one of these three mutations and most BRCA mutations that increase an individual’s risk are not detected by this test,” Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, says in a press release.

“At a minimum, 23andMe should be clear with people about what their test is and isn’t and present the information in a fair and balanced way that the average person can understand,” Ron Rogers, a spokesman for Myraid Genetics, which developed the first BRCA tests, tells STAT News.

According to 23andMe, new and existing customers will have access to the results of the screen several weeks from now.

Correction (March 19): The headline was fixed to state that the FDA has authorized 23andMe to market its test. The agency did not approve the test. For more on the difference, see “Opinion: No, FDA Didn’t Really Approve 23andMe’s BRCA Test.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!